Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Company's filing influential in FDA shunt reclass:

This article was originally published in Clinica

Executive Summary

The US FDA has issued a final guidance document that will allow manufacturers of new endolymphatic shunt tubes with valves to file an abbreviated 510(k) rather than a PMA. The initial guidance document, issued last November in conjunction with a proposed rule reclassifying the product from a high risk, class III, device to a medium risk, class II, device would have required manufacturers to submit a full 510(k) notification. But since then E Benson Hood Laboratories has submitted enough new information on the product that the agency has decided to allow companies to use the less complex abbreviated 510(k) regulatory path in the future.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel